Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?

Benitec Biopharma Limited (BNTC) closed the last trading session at $15.49, gaining 14.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.71 indicates a 66% upside potential.The average comprises seven short-term price targets ranging from a low of $17 to a high of $35, with a standard deviation of $6.70. While the lowest estimate indicates an increase of 9.8% from the current ...